Breakthrough order with new customer in the USA

Shortly before the outbreak of the pandemic, Attana initiated an activity aimed at establishing three reputable reference customers in the United States. Since then, the selected customers have carried out leading experiments with e.g. T cells for palliative care and tissue from biopsies. One of these customers collaborates with a research institute, which has now placed a first small order to perform kinetic interaction analysis of tissue.

The new customer gets access to an existing Attana instrument and begins training users already this month. After that, the customer continues their planned research work during the first half of 2024, which means that they buy chips and advice from Attana. The goal is for the new customer to start the purchasing process for their own instrument within 12 months.

Attana's sales manager Thomas Ljungberg comments:

“This is a very important breakthrough order for us even though the order value is low. The order confirms that our technology is the only one capable of performing this type of kinetic characterization between drug molecule and tissue. We are very pleased that our existing client's results opened up this opportunity with a new client. It is important for our growth, primarily in the American market, but also globally, as they cooperate widely internationally.”

In this scientific article published by 2019, you can read more about how Attana's technology is applied to study the interaction between potential drug candidates and tissue from biopsy samples. These studies provide very valuable information about the effectiveness of a drug molecule and about the condition of the tissue.

For more information, please contact:

Marcus Söderberg

CEO Attana AB
ir@attana.com

+46 708 86 23 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com